CY1124273T1 - Μεθοδοι αγωγης καρκινου στο παγκρεας που περιλαμβανουν πακλιταξελη και γεμσιταβινη - Google Patents

Μεθοδοι αγωγης καρκινου στο παγκρεας που περιλαμβανουν πακλιταξελη και γεμσιταβινη

Info

Publication number
CY1124273T1
CY1124273T1 CY20211100585T CY211100585T CY1124273T1 CY 1124273 T1 CY1124273 T1 CY 1124273T1 CY 20211100585 T CY20211100585 T CY 20211100585T CY 211100585 T CY211100585 T CY 211100585T CY 1124273 T1 CY1124273 T1 CY 1124273T1
Authority
CY
Cyprus
Prior art keywords
gemcitabine
pancreatic cancer
cancer treatments
treatments including
including paclitaxel
Prior art date
Application number
CY20211100585T
Other languages
Greek (el)
English (en)
Inventor
Neil P. Desai
Markus Renschler
Original Assignee
Abraxis Bioscience, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51165317&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1124273(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abraxis Bioscience, Llc filed Critical Abraxis Bioscience, Llc
Publication of CY1124273T1 publication Critical patent/CY1124273T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
CY20211100585T 2013-01-11 2021-06-30 Μεθοδοι αγωγης καρκινου στο παγκρεας που περιλαμβανουν πακλιταξελη και γεμσιταβινη CY1124273T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361751820P 2013-01-11 2013-01-11
US201361752355P 2013-01-14 2013-01-14
US13/794,480 US9511046B2 (en) 2013-01-11 2013-03-11 Methods of treating pancreatic cancer
PCT/US2014/011145 WO2014110443A1 (en) 2013-01-11 2014-01-10 Methods of treating pancreatic cancer

Publications (1)

Publication Number Publication Date
CY1124273T1 true CY1124273T1 (el) 2022-11-25

Family

ID=51165317

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20211100585T CY1124273T1 (el) 2013-01-11 2021-06-30 Μεθοδοι αγωγης καρκινου στο παγκρεας που περιλαμβανουν πακλιταξελη και γεμσιταβινη

Country Status (25)

Country Link
US (3) US9511046B2 (2)
EP (1) EP2943192B9 (2)
JP (3) JP6342918B2 (2)
KR (1) KR102205710B1 (2)
CN (2) CN109793728A (2)
AU (1) AU2013203699B2 (2)
BR (1) BR112015016681A8 (2)
CA (1) CA2897589C (2)
CY (1) CY1124273T1 (2)
DK (1) DK2943192T3 (2)
ES (1) ES2878145T3 (2)
HK (1) HK1216853A1 (2)
HR (1) HRP20211062T1 (2)
HU (1) HUE056612T2 (2)
IL (2) IL239739A0 (2)
LT (1) LT2943192T (2)
MX (1) MX382017B (2)
NZ (2) NZ734971A (2)
PL (1) PL2943192T3 (2)
PT (1) PT2943192T (2)
RS (1) RS62076B1 (2)
SI (1) SI2943192T1 (2)
SM (1) SMT202100377T1 (2)
WO (1) WO2014110443A1 (2)
ZA (1) ZA201504877B (2)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2509365C (en) 2002-12-09 2012-08-07 American Bioscience, Inc. Compositions and methods of delivery of pharmacological agents
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
KR20070114753A (ko) 2005-02-18 2007-12-04 아브락시스 바이오사이언스 인크. 치료제의 조합 및 투여 방식, 및 조합 요법
LT3311805T (lt) 2005-08-31 2020-04-27 Abraxis Bioscience, Llc Kompozicijos, apimančios silpnai vandenyje tirpius farmacinius agentus ir priešmikrobinius agentus
EP3470071A1 (en) 2006-12-14 2019-04-17 Abraxis BioScience, LLC Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane
JP5579057B2 (ja) * 2007-06-01 2014-08-27 アブラクシス バイオサイエンス， エルエルシー 再発性癌の処置のための方法および組成物
PT2419732T (pt) 2009-04-15 2019-12-24 Abraxis Bioscience Llc Composições e métodos de nanopartículas isentas de priões
NZ602382A (en) 2010-03-26 2014-11-28 Abraxis Bioscience Llc Methods of treatment of hepatocellular carcinoma
MX2012011155A (es) 2010-03-29 2012-12-05 Abraxis Bioscience Llc Metodos para mejorar suministros de farmacos y efectividad de agentes terapeuticos.
EP3141245A1 (en) 2010-03-29 2017-03-15 Abraxis BioScience, LLC Methods of treating cancer
MX347225B (es) 2010-06-04 2017-04-19 Abraxis Bioscience Llc * Metodos de tratamiento contra el cancer pancreatico.
JP6031437B2 (ja) * 2010-06-07 2016-11-24 アブラクシス バイオサイエンス， エルエルシー 増殖性疾患を処置するための組み合わせ療法
KR101970342B1 (ko) 2011-04-28 2019-04-18 아브락시스 바이오사이언스, 엘엘씨 나노입자 조성물의 혈관내 전달 및 그의 용도
EP3560486A1 (en) 2011-12-14 2019-10-30 Abraxis BioScience, LLC Use of polymeric excipients for lyophilization or freezing of particles
US9149455B2 (en) 2012-11-09 2015-10-06 Abraxis Bioscience, Llc Methods of treating melanoma
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
EP3698784A1 (en) 2013-03-12 2020-08-26 Abraxis BioScience, LLC Methods of treating lung cancer
RU2015143490A (ru) 2013-03-14 2017-04-26 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи Способы лечения рака мочевого пузыря
US10527604B1 (en) 2015-03-05 2020-01-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel
US10705070B1 (en) 2015-03-05 2020-07-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug
CA3026454C (en) 2015-06-04 2023-07-04 Crititech, Inc. Collection device and methods for use
ES3009356T3 (en) 2015-06-29 2025-03-26 Abraxis Bioscience Llc Nanoparticles comprising sirolimus and an albumin for use in treating epithelioid cell tumors
WO2017003908A1 (en) * 2015-06-30 2017-01-05 The Trustees Of Columbia University In The City Of New York Talc-bound compositions and uses thereof
EP3854381A1 (en) 2016-04-04 2021-07-28 Crititech, Inc. Methods for solid tumor treatment
EP3595717A1 (en) * 2017-03-17 2020-01-22 Imclone, LLC Combination therapy for pancreatic cancer
CA3063420A1 (en) 2017-06-09 2018-12-13 Crititech, Inc. Treatment of epithelial cysts by intracystic injection of antineoplastic particles
WO2018231908A1 (en) 2017-06-14 2018-12-20 Crititech, Inc. Methods for treating lung disorders
KR20250057947A (ko) 2017-10-03 2025-04-29 크리티테크, 인크. 암의 치료를 위한 면역치료제의 전신 전달과 조합된 항신생물성 입자의 국소 전달
IL277402B1 (en) 2018-03-20 2026-04-01 Abraxis Bioscience Llc Methods for treating central nervous system disorders using administration of MTOR inhibitor nanoparticles and albumin
GB201908352D0 (en) * 2019-06-11 2019-07-24 Innovation Ulster Ltd Sonodynamic therapy
US20220332832A1 (en) * 2019-08-01 2022-10-20 New York University Combined cancer therapy of anti-galectin-9 antibodies and chemotherapeutics
BR112022007710A2 (pt) 2019-10-28 2022-07-12 Abraxis Bioscience Llc Composições farmacêuticas de albumina e rapamicina
US20230085602A1 (en) * 2020-02-04 2023-03-16 Swedish Orphan Biovitrum AB (publ ) Pdac treatment regimen
JP2026507878A (ja) * 2023-03-09 2026-03-06 ミネアムリタ セラピューティクス， エルエルシー 膵臓癌の処置のための複合薬
CN117099681B (zh) * 2023-08-28 2024-07-05 南京农业大学 一种利用紫杉醇加倍玉米单倍体的方法

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096331A (en) 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US5439686A (en) 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6753006B1 (en) 1993-02-22 2004-06-22 American Bioscience, Inc. Paclitaxel-containing formulations
US5650156A (en) 1993-02-22 1997-07-22 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of nutriceuticals and compositions useful therefor
US5362478A (en) 1993-03-26 1994-11-08 Vivorx Pharmaceuticals, Inc. Magnetic resonance imaging with fluorocarbons encapsulated in a cross-linked polymeric shell
NZ262679A (en) 1993-02-22 1997-08-22 Vivorx Pharmaceuticals Inc Compositions for in vivo delivery of pharmaceutical agents where the agents are contained in a polymeric shell
US5997904A (en) 1993-02-22 1999-12-07 American Bioscience, Inc. Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof
US6537579B1 (en) 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
US20030068362A1 (en) 1993-02-22 2003-04-10 American Bioscience, Inc. Methods and formulations for the delivery of pharmacologically active agents
US5916596A (en) 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6528067B1 (en) 1993-02-22 2003-03-04 American Bioscience, Inc. Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof
US6565842B1 (en) 1995-06-07 2003-05-20 American Bioscience, Inc. Crosslinkable polypeptide compositions
US8137684B2 (en) 1996-10-01 2012-03-20 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
PT1023050E (pt) 1997-06-27 2013-12-04 Abraxis Bioscience Llc Novas formulações de agentes farmacológicos, métodos para a sua preparação e métodos para a sua utilização
US20030199425A1 (en) 1997-06-27 2003-10-23 Desai Neil P. Compositions and methods for treatment of hyperplasia
US8853260B2 (en) 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
EP1171117A4 (en) 1999-04-22 2002-08-07 American Bioscience Inc LONG-TERM ADMINISTRATION OF PHARMACOLOGICALLY ACTIVE AGENTS
HK1045646A1 (zh) 1999-05-21 2002-12-06 Abraxis Bioscience, Llc 蛋白質穩定化的藥理學活性劑，其製備方法及其使用方法
ITMI20001107A1 (it) 2000-05-18 2001-11-18 Acs Dobfar Spa Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel
ITMI20020681A1 (it) * 2002-03-29 2003-09-29 Acs Dobfar Spa Procedimento per la produzione di nanoparticelle di paclitaxel ed albumina
KR20120068035A (ko) 2002-12-09 2012-06-26 아브락시스 바이오사이언스, 엘엘씨 약리학적 물질의 조성물 및 그 전달방법
CA2509365C (en) 2002-12-09 2012-08-07 American Bioscience, Inc. Compositions and methods of delivery of pharmacological agents
KR20070114753A (ko) 2005-02-18 2007-12-04 아브락시스 바이오사이언스 인크. 치료제의 조합 및 투여 방식, 및 조합 요법
AU2012201568B2 (en) 2005-02-18 2014-07-31 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
US20070166388A1 (en) 2005-02-18 2007-07-19 Desai Neil P Combinations and modes of administration of therapeutic agents and combination therapy
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
MX2007013494A (es) * 2005-04-29 2008-01-24 Kosan Biosciences Inc Metodo para tratar mieloma multiple utilizando 17-aag o 17-ag o un profarmaco de ya sea 17-aag o 17-ag.
LT3311805T (lt) 2005-08-31 2020-04-27 Abraxis Bioscience, Llc Kompozicijos, apimančios silpnai vandenyje tirpius farmacinius agentus ir priešmikrobinius agentus
EP3527202A1 (en) 2005-08-31 2019-08-21 Abraxis BioScience, LLC Compositions and methods for preparation of poorly water soluble drugs with increased stability
JP2007297339A (ja) * 2006-04-29 2007-11-15 Torii Yakuhin Kk 癌を治療又は検査するための医薬
EP2056812A1 (en) 2006-08-31 2009-05-13 Abraxis BioScience, LLC Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases
EP3470071A1 (en) 2006-12-14 2019-04-17 Abraxis BioScience, LLC Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane
EP2131821B1 (en) 2007-03-07 2018-05-09 Abraxis BioScience, LLC Nanoparticle comprising rapamycin and albumin as anticancer agent
US20100166869A1 (en) 2007-05-03 2010-07-01 Desai Neil P Methods and compositions for treating pulmonary hypertension
JP5579057B2 (ja) 2007-06-01 2014-08-27 アブラクシス バイオサイエンス， エルエルシー 再発性癌の処置のための方法および組成物
MX2010011165A (es) 2008-04-10 2011-02-22 Abraxis Bioscience Llc Composiciones de derivados de taxano hidrofobos y sus usos.
TW200942233A (en) 2008-04-10 2009-10-16 Abraxis Bioscience Llc Compositions of hydrophobic taxane derivatives and uses thereof
US9120854B2 (en) * 2008-04-11 2015-09-01 Seattle Genetics, Inc. Detection and treatment of pancreatic, ovarian and other cancers
CA2746129A1 (en) 2008-12-11 2010-06-17 Abraxis Bioscience, Llc Combination chemotherapy of nanoparticulate taxanes and inhibitors of pro-survival and/or inflammatory signals
GB0900555D0 (en) 2009-01-14 2009-02-11 Topotarget As New methods
WO2010105172A1 (en) 2009-03-13 2010-09-16 Abraxis Bioscience, Llc Combination therapy with thiocolchicine derivatives
CA2758200A1 (en) 2009-04-10 2010-10-14 Abraxis Bioscience, Llc Nanoparticle formulations and uses thereof
PT2419732T (pt) 2009-04-15 2019-12-24 Abraxis Bioscience Llc Composições e métodos de nanopartículas isentas de priões
CA2960887C (en) * 2009-05-28 2018-09-04 Abraxis Bioscience, Llc Use of 2 anti-sparc antibodies to predict response to chemotherapy
EP3103452A1 (en) 2009-08-25 2016-12-14 Abraxis BioScience, LLC Combination therapy with nanoparticle compositions of taxane and hedgehog inhibitors
JP2011079788A (ja) * 2009-10-08 2011-04-21 Oita Univ 膵癌に対する選択的膵動脈制癌剤注入療法と全身化学療法との併用療法、およびそれに使用する膵癌治療薬
NZ601324A (en) * 2010-01-05 2014-10-31 Vascular Biogenics Ltd Methods for use of a specific anti-angiogenic adenoviral agent
NZ602382A (en) 2010-03-26 2014-11-28 Abraxis Bioscience Llc Methods of treatment of hepatocellular carcinoma
MX2012011155A (es) 2010-03-29 2012-12-05 Abraxis Bioscience Llc Metodos para mejorar suministros de farmacos y efectividad de agentes terapeuticos.
EP3141245A1 (en) 2010-03-29 2017-03-15 Abraxis BioScience, LLC Methods of treating cancer
WO2011121453A2 (en) 2010-03-30 2011-10-06 Clavis Pharma Asa Methods and compositions for treating or ameliorating cancer using gemcitabine-5'-elaidate
CA2801314A1 (en) 2010-06-02 2011-12-08 Abraxis Bioscience, Llc Methods of treating bladder cancer
MX347225B (es) 2010-06-04 2017-04-19 Abraxis Bioscience Llc * Metodos de tratamiento contra el cancer pancreatico.
JP6031437B2 (ja) 2010-06-07 2016-11-24 アブラクシス バイオサイエンス， エルエルシー 増殖性疾患を処置するための組み合わせ療法
KR101970342B1 (ko) 2011-04-28 2019-04-18 아브락시스 바이오사이언스, 엘엘씨 나노입자 조성물의 혈관내 전달 및 그의 용도
EP3560486A1 (en) 2011-12-14 2019-10-30 Abraxis BioScience, LLC Use of polymeric excipients for lyophilization or freezing of particles
US9149455B2 (en) 2012-11-09 2015-10-06 Abraxis Bioscience, Llc Methods of treating melanoma
US20140186447A1 (en) 2012-12-28 2014-07-03 Abraxis Bioscience, Llc Nanoparticle compositions of albumin and paclitaxel
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
US20140199404A1 (en) 2013-01-11 2014-07-17 Abraxis Bioscience, Llc Method for treating cancer based on level of a nucleoside transporter
US20140199405A1 (en) 2013-01-11 2014-07-17 Abraxis Bioscience, Llc Method for treating cancer based on mutation status of k-ras
KR102148551B1 (ko) 2013-02-11 2020-08-26 아브락시스 바이오사이언스, 엘엘씨 흑색종을 치료하는 방법
EP3698784A1 (en) 2013-03-12 2020-08-26 Abraxis BioScience, LLC Methods of treating lung cancer
JP6387389B2 (ja) 2013-03-13 2018-09-05 アブラクシス バイオサイエンス， エルエルシー 小児充実性腫瘍の処置の方法
RU2015143490A (ru) 2013-03-14 2017-04-26 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи Способы лечения рака мочевого пузыря
WO2015157120A1 (en) 2014-04-06 2015-10-15 Abraxis Bioscience, Llc Combination therapy comprising nanoparticles of a taxane and albumin with abt-263 in methods for treating cancer
WO2016141365A1 (en) 2015-03-05 2016-09-09 Abraxis Bioscience, Llc Method for treating cancer based on level of glucocorticoid receptor
KR20240144442A (ko) 2015-06-29 2024-10-02 아브락시스 바이오사이언스, 엘엘씨 나노입자 조성물에 대한 바이오마커
ES3009356T3 (en) 2015-06-29 2025-03-26 Abraxis Bioscience Llc Nanoparticles comprising sirolimus and an albumin for use in treating epithelioid cell tumors
JP2018521058A (ja) 2015-06-29 2018-08-02 アブラクシス バイオサイエンス， エルエルシー ナノ粒子ｍＴＯＲ阻害剤併用治療を使用して固形腫瘍を処置する方法
US20170181988A1 (en) 2015-12-23 2017-06-29 Cipla Limited Methods for the treatment of bladder cancer

Also Published As

Publication number Publication date
AU2013203699B2 (en) 2016-09-08
US10328031B2 (en) 2019-06-25
CN109793728A (zh) 2019-05-24
US20170020824A1 (en) 2017-01-26
SMT202100377T1 (it) 2022-01-10
HUE056612T2 (hu) 2022-02-28
PT2943192T (pt) 2021-07-16
ZA201504877B (en) 2016-10-26
ES2878145T3 (es) 2021-11-18
CN105025893A (zh) 2015-11-04
IL272905A (en) 2020-04-30
NZ734971A (en) 2018-12-21
HK1216853A1 (zh) 2016-12-09
MX2015008898A (es) 2015-10-14
NZ630230A (en) 2017-09-29
WO2014110443A1 (en) 2014-07-17
CA2897589C (en) 2021-03-02
MX382017B (es) 2025-03-11
RS62076B1 (sr) 2021-07-30
JP2019081790A (ja) 2019-05-30
LT2943192T (lt) 2021-08-10
JP2018087235A (ja) 2018-06-07
BR112015016681A2 (pt) 2017-07-11
EP2943192A1 (en) 2015-11-18
JP2016505018A (ja) 2016-02-18
JP6342918B2 (ja) 2018-06-13
US20180153820A1 (en) 2018-06-07
PL2943192T3 (pl) 2022-01-24
CA2897589A1 (en) 2014-07-17
DK2943192T3 (da) 2021-07-05
EP2943192A4 (en) 2016-06-01
HRP20211062T1 (hr) 2021-12-24
AU2013203699A1 (en) 2014-10-30
EP2943192B9 (en) 2021-09-29
KR20150103745A (ko) 2015-09-11
EP2943192B1 (en) 2021-05-12
JP6697017B2 (ja) 2020-05-20
BR112015016681A8 (pt) 2019-10-22
IL239739A0 (en) 2015-08-31
SI2943192T1 (sl) 2021-09-30
US9855220B2 (en) 2018-01-02
KR102205710B1 (ko) 2021-01-21
US20140199403A1 (en) 2014-07-17
US9511046B2 (en) 2016-12-06

Similar Documents

Publication Publication Date Title
CY1124273T1 (el) Μεθοδοι αγωγης καρκινου στο παγκρεας που περιλαμβανουν πακλιταξελη και γεμσιταβινη
CY1124926T1 (el) Νανοσωματιδια που περιλαμβανουν σιρολιμους και μια αλβουμινη για χρηση στη θεραπεια ογκων απο επιθηλιοειδη κυτταρα
MX389667B (es) Antagonistas de unión al eje pd-1 y taxanos para usarse en el tratamiento de cáncer.
CY1121907T1 (el) Συζευγματα antidll3-antiσωmatoς-pbd και χρησεις αυτων
CY1122478T1 (el) Συνθεσεις που περιεχουν anti-cd38 αντισωματα και λεναλιδομιδη
EA201992251A1 (ru) Противораковые вакцины и способы лечения с их применением
MX2015010312A (es) Metodos para tratamiento del melanoma.
MX2015008888A (es) Metodo para tratar el cancer basado en el nivel de un transportador de nucleosido.
CL2015003280A1 (es) Derivados de benzimidazol como inhibidores de bromodominio
CL2015002472A1 (es) Como inhibidores de mutant idh-yl-oxazolidin-2-onas 3-pirimidin-4.
MX393818B (es) Terapias de combinación para el tratamiento de cáncer.
MX369863B (es) Ciertas entidades quimicas, composiciones y metodos.
NI201200175A (es) Métodos de tratamiento de cáncer de vejiga
MX2016001236A (es) Anticuerpos anti-fgfr2iiib afucosilados.
CY1123019T1 (el) Σπειροκυκλικες ενωσεις
MX2016004441A (es) Tratamiento del cancer con una combinacion de plinabulina y taxano.
MX2015011606A (es) Metodo para tratar cancer y prevenir resistencia a farmacos contra cancer.
CY1121821T1 (el) Θεραπεια συνδυασμου για την αγωγη του καρκινου των ωοθηκων
MX2018003301A (es) Inhibidores de pcna.
CY1122998T1 (el) Μεθοδοι και συνθεσεις για την αντιμετωπιση της καταθλιψης χρησιμοποιωντας κυκλοβενζαπρινη
MX2015014590A (es) Tratamiento de cancer con dihidropirazino-pirazinas.
ECSP14011792A (es) Inhibidores de iap
PH12017501879A1 (en) Methods for treating cancer
CY1122403T1 (el) Μορφες δοσολογιας και θεραπευτικες χρησεις της l-4-χλωροκυνουρενινης
CY1124709T1 (el) Φαρμακο κατα των ογκων που περιεχει συμπλοκο λευκοχρυσου κατα των ογκων και επαυξητη επιδρασης κατα των ογκων